PE20000323A1 - Antagonistas de receptor de vitronectina - Google Patents

Antagonistas de receptor de vitronectina

Info

Publication number
PE20000323A1
PE20000323A1 PE1999000188A PE00018899A PE20000323A1 PE 20000323 A1 PE20000323 A1 PE 20000323A1 PE 1999000188 A PE1999000188 A PE 1999000188A PE 00018899 A PE00018899 A PE 00018899A PE 20000323 A1 PE20000323 A1 PE 20000323A1
Authority
PE
Peru
Prior art keywords
alkyl
het
compound
vitronectin receptor
chrg
Prior art date
Application number
PE1999000188A
Other languages
English (en)
Inventor
William H Miller
Dirk Heerding
James M Samanen
John G Gleason
Irene N Uzinskas
Peter J Manley
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of PE20000323A1 publication Critical patent/PE20000323A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72Nitrogen atoms
    • C07D213/74Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32One oxygen, sulfur or nitrogen atom
    • C07D239/42One nitrogen atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

SE REFIERE A UN COMPUESTO DE FORMULA I DONDE R* ES -X-CH(-R1)-CH2-CO2H, -CH2-N(-R1)-CH2-CO2H, -Cl; X E Y SON CR`R', NR', S; A ES H, HALO, ORg, -SRg, CN, NRgRk, -NO2, -CF3, ENTRE OTROS; R1 ES -ALQUIL C0-C6(HET), -(ALQUIL C0-C6)Ar, ENTRE OTROS; R2 ES UN GRUPO DE FORMULA a, b, ENTRE OTROS; W ES -(CHRg)a-U-(CHRg)b-; U ESTA AUSENTE O ES CO, C(Rg)2, C(=CRg2), S(O)k, ENTRE OTROS; G ES NRe, S, O; Rg ES H, ALQUILO C1-C6, HET(ALQUILO C0-C6), ENTRE OTROS; Rk ES Rg, -CORg, -COORf; Ri ES H, ALQUILO C1-C6, HET(ALQUILO C0-C6), ENTRE OTROS; Rf ES H, ALQUILO C1-C6, Ar(ALQUILO C0-C6); Re ES H, ALQUILO C1-C6, Ar(ALQUILO C1-C6); Rb Y Rc SON H, ALQUILO C1-C6, Ar(ALQUILO C0-C6), ENTRE OTROS; UNO DE Q1, Q2, Q3, Q4 ES N Y EL RESTO ES CRy; R' ES H, ALQUILO C1-C6, Ar-ALQUILO C0-C6; R'' ES R', COR', COOR'; RY ES H, HALO, CRg, SRg, CN, ENTRE OTROS; a, b, k, r Y s SON 0-2; u Y v SON 0-1. UN COMPUESTO PREFERIDO ES ACIDO (+/-)-3-FENIL-4-[4-[3-(PIRIDIN-2-IL)AMINO-1-PROPIL-OXI]FENIL]BUTANOICO, ENTRE OTROS. TAMBIEN SE REFIERE A UN PROCEDIMIENTO PARA LA PREPARACION. EL COMPUESTO I ES UN ANTAGONISTA DEL RECEPTOR DE VITRONECTINA Ovß3 Y Ovß5 Y PUEDE SER UTIL PARA EL TRATAMIENTO DE LA OSTEOPOROSIS, INFLAMACION, CANCER, TRASTORNOS CARDIOVASCULARES TALES COMO ATEROSCLEROSIS Y RESTENOSIS
PE1999000188A 1998-03-10 1999-03-10 Antagonistas de receptor de vitronectina PE20000323A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7761098P 1998-03-10 1998-03-10
US9606398P 1998-08-11 1998-08-11

Publications (1)

Publication Number Publication Date
PE20000323A1 true PE20000323A1 (es) 2000-05-24

Family

ID=26759473

Family Applications (1)

Application Number Title Priority Date Filing Date
PE1999000188A PE20000323A1 (es) 1998-03-10 1999-03-10 Antagonistas de receptor de vitronectina

Country Status (24)

Country Link
EP (1) EP1061921A4 (es)
JP (1) JP2002506033A (es)
KR (1) KR20010041812A (es)
CN (1) CN1299282A (es)
AP (1) AP2000001898A0 (es)
AR (1) AR015241A1 (es)
AU (1) AU758498B2 (es)
BG (1) BG104824A (es)
BR (1) BR9908636A (es)
CA (1) CA2323208A1 (es)
CO (1) CO5080762A1 (es)
DZ (1) DZ2741A1 (es)
EA (1) EA200000921A1 (es)
HU (1) HUP0101143A3 (es)
ID (1) ID26223A (es)
IL (1) IL138245A0 (es)
NO (1) NO20004503L (es)
OA (1) OA12189A (es)
PE (1) PE20000323A1 (es)
PL (1) PL342881A1 (es)
SK (1) SK13292000A3 (es)
TR (1) TR200002625T2 (es)
UY (2) UY25421A1 (es)
WO (1) WO1999045927A1 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19939981A1 (de) * 1999-08-24 2001-03-01 Merck Patent Gmbh Neue Inhibitoren des Integrins alphavß3
DE19939980A1 (de) * 1999-08-24 2001-03-01 Merck Patent Gmbh Inhibitoren des Integrins alphavbeta¶3¶
US6881736B1 (en) 1999-09-07 2005-04-19 Smithkline Beecham Corporation Vitronectin receptor antagonists
EG24179A (en) * 1999-09-07 2008-09-28 Smithkline Beecham Corp Vitronectin receptor antagonists
GB9930570D0 (en) * 1999-12-23 2000-02-16 Pfizer Ltd Therapy
US6448278B2 (en) 1999-12-23 2002-09-10 Pfizer Inc. Procollagen C-proteinase inhibitors
FR2808798A1 (fr) * 2000-05-09 2001-11-16 Hoechst Marion Roussel Inc Nouveaux derives antagonistes du recepteur de la vitronectine
PE20020665A1 (es) 2000-06-15 2002-08-14 Pharmacia Corp ACIDO CICLOALQUIL FENIL ALCANOICO COMO ANTAGONISTA DE INTEGRINAS OVß3
US6531494B1 (en) 2001-08-29 2003-03-11 Pharmacia Corporation Gem-substituted αvβ3 antagonists
US6645993B2 (en) 2001-03-30 2003-11-11 Warner-Lambert Company 3-heterocyclylpropanohydroxamic acid PCP inhibitors
US6716842B2 (en) 2002-04-05 2004-04-06 Warner-Lambert Company, Llc Antidiabetic agents
WO2005049589A2 (en) * 2003-10-14 2005-06-02 Cadila Healthcare Limited Heterocyclic compounds for the treatment of hyperlipidemia, diabetes, obesity and similar diseases
EP1721905A4 (en) * 2004-03-05 2009-11-18 Taisho Pharmaceutical Co Ltd THIAZOLE DERIVATIVE
UA87854C2 (en) 2004-06-07 2009-08-25 Мерк Энд Ко., Инк. N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators
MX2007013198A (es) 2005-04-20 2008-03-24 Johnson & Johnson Moduladores de trombina de n-oxido de piridina fluorado y procedimiento para n-oxidacion de heteroarilos que contienen nitrogeno.
AU2014312756B2 (en) * 2013-08-29 2018-11-22 Kyoto Pharmaceutical Industries, Ltd. Novel aromatic compound and use thereof
HUE063437T2 (hu) 2013-09-24 2024-01-28 Fujifilm Corp Nitrogént tartalmazó vegyületet vagy sóját vagy fémkomplexét tartalmazó gyógyászati készítmény
KR20160147007A (ko) 2014-05-30 2016-12-21 화이자 인코포레이티드 선택적인 안드로겐 수용체 조절제로서의 카보니트릴 유도체
WO2023275715A1 (en) 2021-06-30 2023-01-05 Pfizer Inc. Metabolites of selective androgen receptor modulators

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL327626A1 (en) * 1995-12-29 1998-12-21 Smithkline Beecham Corp Antagonists of vitronectin receptor
IL125034A0 (en) * 1995-12-29 1999-01-26 Smithkline Beecham Corp Vitronectin receptor antagonists

Also Published As

Publication number Publication date
TR200002625T2 (tr) 2000-12-21
UY25519A1 (es) 1999-12-13
EP1061921A1 (en) 2000-12-27
EA200000921A1 (ru) 2001-04-23
HUP0101143A3 (en) 2002-12-28
IL138245A0 (en) 2001-10-31
CO5080762A1 (es) 2001-09-25
NO20004503L (no) 2000-10-10
ID26223A (id) 2000-12-07
AP2000001898A0 (en) 2000-09-30
CA2323208A1 (en) 1999-09-16
WO1999045927A1 (en) 1999-09-16
EP1061921A4 (en) 2005-03-30
OA12189A (en) 2006-05-09
HUP0101143A2 (hu) 2001-08-28
AU758498B2 (en) 2003-03-20
AU2903399A (en) 1999-09-27
UY25421A1 (es) 2001-07-31
CN1299282A (zh) 2001-06-13
SK13292000A3 (sk) 2001-06-11
DZ2741A1 (fr) 2003-09-08
JP2002506033A (ja) 2002-02-26
AR015241A1 (es) 2001-04-18
BR9908636A (pt) 2002-01-08
PL342881A1 (en) 2001-07-16
BG104824A (en) 2001-05-31
NO20004503D0 (no) 2000-09-08
KR20010041812A (ko) 2001-05-25

Similar Documents

Publication Publication Date Title
PE20000323A1 (es) Antagonistas de receptor de vitronectina
ES2330552T3 (es) Derivados de pirimidin-5-ona como inhibidores de ldl-pla2.
AU711438B2 (en) 7-amino-1H-indol derivatives
KR960003604B1 (en) Benzimidazoline-2-oxo-1-carboxylic acid derivatives
WO2006022442A1 (ja) ジヒドロオロテートデヒドロゲナーゼ阻害活性を有する新規複素環アミド誘導体
AU2004257639A1 (en) Pyrimidine-2, 4-dione derivatives as gonadotropin-releasing hormone receptor antagonists
AU2003301853B2 (en) Indoles useful in the treatment of androgen- receptor related diseases
CZ2000431A3 (cs) Chemické sloučeniny s protizánětlivou aktivitou obsahující indolovou skupinu, způsob jejich přípravy, použití a farmaceutické prostředky, které je obsahují
DE60014393D1 (de) Aminobenzophenone als inhibitoren von il-1beta und tnf-alpha
WO2001072708A3 (en) OXINDOLE INHIBITORS OF FACTOR Xa
MX2007005566A (es) Sulfamidas como antagonistas de receptor de endotelina para el tratamiento de enfermedades cardiovasculares.
US6048823A (en) Pyridone derivatives and herbicides
AP2003002810A0 (en) 1,4-Disubstituted piperazine derivatives useful as uro-selective a, - adrenoceptor blockers
US8124647B2 (en) Non-steroidal androgens compounds
PE20010649A1 (es) Derivados de antranilamida de piperidinas 1,4-di-sustituidas como antagonistas muscarinicos
PL169764B1 (pl) Srodek chwastobójczy PL PL
EA200001009A1 (ru) Производные пиридина, ингибирующие фосфодиэстеразу iv
PE20021154A1 (es) Derivados de 4-aminopirimidina como antagonistas del receptor metabotropico de glutamato
PE20010582A1 (es) Antagonistas de los receptores de vitronectina
CA2374643A1 (en) 1-trifluoromethyl-4-hydroxy-7-piperidinylaminomethylchroman derivatives as substance p antagonists
Khan et al. A facile synthesis of novel unsymmetrical N-(4-oxo-2-phenyl-3 (4H)-quinazolinoyl)-N-(aryl) acetamidines
Wu et al. Design and synthesis of aminophenol-Based factor xa inhibitors
ATE246680T1 (de) Spiroimidazolinderivate und ihre verwendung als alpha2-adrenorezeptor-antagonisten und monoamino- wiederaufnahme-blocker
JP2007502259A (ja) マトリックスメタロプロテイナーゼの阻害剤
PE20001520A1 (es) Composiciones farmaceuticas que comprenden derivados sustituidos de indazol como inhibidores de pde tipo iv y la produccion de tnf

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed